02 Dec, 15:19 - Indian

SENSEX 80212.7 (0.51)

Nifty 50 24261 (0.54)

Nifty Bank 52073.3 (0.03)

Nifty IT 43526.4 (0.88)

Nifty Midcap 100 56981.05 (1.04)

Nifty Next 50 71164.35 (0.62)

Nifty Pharma 22439.15 (0.89)

Nifty Smallcap 100 18843.15 (1.03)

02 Dec, 15:19 - Global

NIKKEI 225 38513.02 (0.80)

HANG SENG 19550.29 (0.65)

S&P 6051.75 (-0.19)

Login/Signup

You are Here : Home > Research

08-May-2024

Dr Reddys Laboratories

NP up 36.42%

'For the quarter ending March 2024, consolidated net sales (including other operating income) of Dr Reddys Laboratories has increased 12.65% to Rs 7113.8 crore compared to quarter ended March 2023.  Sales of Pharmaceutical Services segment has gone up 12.76% to Rs 1,172.50 crore (accounting for 15.75% of total sales).  Sales of Global Generics segment has gone up 12.88% to Rs 6,128.90 crore (accounting for 82.33% of total sales).  Sales of Others segment has gone up 53.71% to Rs 143.10 crore (accounting for 1.92% of total sales).  Inter-segment sales rose Rs 247.40 crore to Rs 330.70 crore.  

Profit before interest, tax and other unallocable items (PBIT) has jumped 15.23% to Rs 4,148.80 crore.  PBIT of Pharmaceutical Services segment rose 19.24% to Rs 234.90 crore (accounting for 5.66% of total PBIT).  PBIT of Global Generics segment rose 13.25% to Rs 3,793.70 crore (accounting for 91.44% of total PBIT).&nb...



Pleaselogin & subscribe to view the full report.

More Reports
More Reports View Company Information